Micro-dose Tirzepatide + B12 for Weight Loss

Micro-dose Tirzepatide + B12 for Weight Loss

FSA / HSA Eligible

$199 / Month

Micro-Dose

  • Transparent pricing with no hidden fees

  • No insurance needed

  • Doctor prescribed

  • FSA/HSA Eligible

Microdosing Tirzepatide for Lasting Results

Experience a smarter, gentler way to reach your health goals with microdosed Tirzepatide. This next-generation treatment targets two key hormone receptors (GIP and GLP-1) to help regulate appetite, improve blood sugar, and support steady, sustainable weight loss.

By starting with microdoses, your body adjusts gradually—reducing side effects while maintaining powerful results. Clinical research shows Tirzepatide can significantly lower blood sugar, reduce body fat, and improve overall metabolic health. It’s a breakthrough approach for anyone looking to enhance wellness, manage weight, or improve energy with a more balanced, science-backed solution.

References

Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022). Tirzepatide: A Systematic Update. International journal of molecular sciences, 23(23), 14631. 

https://pubmed.ncbi.nlm.nih.gov/36498958/

Tang, Y., Zhang, L., Zeng, Y., Wang, X., & Zhang, M. (2022). Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis. Frontiers in pharmacology, 13, 1016639. 

https://pubmed.ncbi.nlm.nih.gov/36569320/

Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025). The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials. Pharmaceuticals (Basel, Switzerland), 18(5), 668.

https://pubmed.ncbi.nlm.nih.gov/40430487/

Razzaki, T. S., Weiner, A., & Shukla, A. P. (2022). Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes?. Therapeutics and clinical risk management, 18, 955–964. 

https://pubmed.ncbi.nlm.nih.gov/36199834/

Tan, B., Pan, X. H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., Chung, H. C., Young, D. Y., Chan, M. Y., Khoo, C. M., Mehta, A., Muthiah, M. D., Noureddin, M., Ng, C. H., Chew, N. W. S., & Chin, Y. H. (2023). Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. International journal of obesity (2005), 47(8), 677–685. 

https://pubmed.ncbi.nlm.nih.gov/37253796/

Gudzune, K. A., & Kushner, R. F. (2024). Medications for obesity: A review. JAMA, 332(7), 571-584. doi:10.1001/jama.2024.10816.

https://pubmed.ncbi.nlm.nih.gov/39037780/

Lin, F., Yu, B., Ling, B., Lv, G., Shang, H., Zhao, X., Jie, X., Chen, J., & Li, Y. (2023). Weight loss efficiency and safety of tirzepatide: A Systematic review. PloS one, 18(5), e0285197. 

https://pubmed.ncbi.nlm.nih.gov/37141329/

Aminorroaya, A., Oikonomou, E. K., Biswas, D., Jastreboff, A. M., & Khera, R. (2025). Effects of tirzepatide in type 2 diabetes: Individual variation and relationship to cardiometabolic outcomes. Journal of the American College of Cardiology, 85(19), 1858-1872. 

https://pubmed.ncbi.nlm.nih.gov/40368575/

Fiorucci, S., & Urbani, G. (2025). Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives. Expert opinion on investigational drugs, 10.1080/13543784.2025.2546812. Advance online publication. 

https://pubmed.ncbi.nlm.nih.gov/40782123/

Sattar, N., García-Pérez, L. E., Rodríguez, A., Kapoor, R., Stefanski, A., & Hankosky, E. R. (2025). Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence. Diabetes, obesity & metabolism, 10.1111/dom.16549. Advance online publication. 

https://pubmed.ncbi.nlm.nih.gov/40555920/

Experience The Future Of Metabolic Optimization With Nucore.